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Background: Cardiovascular events (CVE) are more prevalent in chronic kidney disease (CKD) than in general
population, being the main cause of morbimortality. Specific risk factors related to CKD have been suggested,
because traditional factors do not fully explain this increase in cardiovascular disease rates. However, the role of
atheromatosis, its pathogenesis and evolution are still unclear. The potential use of diagnostic tests to detect
subclinical atheromatosis has to be determined.
Methods: NEFRONA is a prospective multicenter cohort study. 2445 CKD subjects were enrolled from 81 Spanish
hospitals and dialysis clinics, from 2010 to 2012. Eligibility criteria included: 18 to 74 years old, CKD stage 3 or
higher, and no previous CVE. 559 non-CKD controls were also recruited. Demographical, clinical and analytical data
were collected. Carotid and femoral ultrasounds were performed by a single trained team to measure carotid
intima-media thickness (cIMT) and detect atheromatous plaques. Ankle-brachial index (ABI) was measured.
Results: Differences in age, sex and prevalence and control of cardiovascular risk factors were found between
controls and CKD patients. These differences are similar to those described in epidemiological studies.
No difference was found regarding cIMT between controls and CKD (when subjects with plaques in common carotid
arteries were omitted); earlier CKD stages had higher values. CKD patients had a higher rate of atheromatous plaques,
with no difference between stages in the unadjusted analysis. A group of patients had plaques in femoral arteries but
were plaque-free in carotid arteries, and would have gone underdiagnosed without the femoral study. The percentage
of pathologic ABI was higher in CKD, with higher prevalence in more advanced stages, and a higher rate of ABI >1.4
than <0.9, suggesting more vascular calcification.
Conclusions: NEFRONA is the first large study describing the actual prevalence of subclinical atheromatosis across
different CKD stages. There is a very high rate of atheromatous plaques and pathologic ABI in CKD. Prospective
data will add important information to the pathogenesis and evolution of atheromatosis in CKD, compared to
non-CKD subjects.
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Chronic kidney disease (CKD) is a growing health prob-
lem, with increasing morbidity, mortality and monetary
costs [1]. Despite the improvement in the treatment of
its complications, patients with CKD in any stage con-
tinue to have a higher rate of cardiovascular events than
subjects with normal renal function. In fact, cardiovascu-
lar disease (CVD) continues to be the first mortality
cause in this population, and in many recent guidelines
it has been stated as a cardiovascular risk factor itself, as
severe as diabetes [2].
Important advances have been made in the knowledge
of both general and specific cardiovascular risk factors in
CKD. However, neither traditional risk factors or risk
score charts for general population nor emerging risk
biomarkers appear to be good enough predictors in this
population [3-6]. It has been suggested that there is a dif-
ferent pathogenesis for CVD in advanced CKD, since
most cardiovascular deaths appear to be from sudden
deaths. These events have been related to possible ar-
rhythmias or heart failure, related to heart remodelling
and microischemia of the myocardium [7-9]. Besides, the
effects of reverse epidemiology of many traditional risk
factors and the appearance of different mechanisms are
involved [10-12].
The presence of accelerated atheromatosis in CKD
could also play a role in the higher cardiovascular mor-
tality, in a process that has been termed accelerated
vascular aging. However, there is still much to clarify
regarding the process of atheromatosis in this group of
patients, and the precise contribution of various risk fac-
tors. Many serum biomarkers are altered in CKD pa-
tients, and their prognostic value is currently under study
[13,14], but new tools for adequately assessing asymp-
tomatic atheromatosis are required [15]. The application
of diagnostic tests in CKD (i.e. vascular ultrasound or
ankle-brachial index) to detect subclinical atheromatosis
and adequately stratify cardiovascular risk has not yet
been specifically addressed, although there are some ini-
tial promising data [16,17].
The NEFRONA project is an observational multicen-
ter prospective study designed to evaluate the prevalence
and evolution of subclinical atheromatosis in CKD pa-
tients, as well as the contribution of vascular imaging for a
more precise cardiovascular risk assessment [18,19]. Base-
line data of this study are presented in this article.
Methods
Study design and participants
NEFRONA is a prospective multicenter cohort study, in
which 2445 CKD subjects were enrolled in 81 Spanish
hospitals and dialysis clinics, from October 2010 to June
2012. Patients between 18 and 74 years of age were eli-
gible if they had CKD stage 3 or higher as defined bycurrent guidelines (glomerular filtration rate lower than
60 mL/min/1.73 m2 estimated using the 4-variable
Modification of Diet in Renal Disease (MDRD) equation)
[20]. Besides, 559 controls with an MDRD over 60 mL/
min/1.73 m2 were recruited from Primary Care centers.
Exclusion criteria for both groups included: active infec-
tions, pregnancy, life expectancy lower than 12 months,
and history of cardiovascular events, carotid artery surgery
or any organ transplantation.
The sample size was calculated based on the incidence
of cardiovascular events described in the CKD popula-
tion and depending on the stage of kidney disease [21].
The minimum sample required is based on the number
of cases studied to obtain a minimum number of events
(assumed to be homogeneously distributed throughout
the follow-up period) to adjust the results of the multi-
variate analysis for 15 variables. We fixed type I and II
errors to 5% (bilateral) and 10%, respectively. It was as-
sumed a 25% loss of follow-up, and that both events and
losses of follow-up will be proportionally distributed
over the study period. Consequently, it was planned to
include a total of 2661 patients (1325 stage 3 CKD, 713
stage 4 and 5 CKD, and 623 in dialysis). Furthermore,
843 subjects without renal disease were planned to be
included to detect significant differences in the presence of
plaques among patients for each stage of kidney disease
and subjects without kidney disease (estimated from data
provided by the Hospital Arnau de Vilanova, Lleida).
Patients were provided with and signed an informed
consent. The local Ethics Committee of the Hospital
Arnau de Vilanova approved the protocol.
Clinical and laboratory data
Recruiting investigators completed a questionnaire with
the patients’ clinical data, including family history of early
cardiovascular disease, cardiovascular risk factors (such
as smoking, diabetes, hypertension or dyslipidemia) and
current medications. Anthropometrical data and vitals
were obtained using standardized methods, as described
in the study design [18]. Intact parathyroid hormone, 25-
hydroxi-vitamin D and 1,25-hydroxi-vitamin D were all
measured in a centralized laboratory.
Biochemical parameters were obtained from a routine
fasting blood test taken no more than three months
apart from the vascular explorations. In hemodialysis pa-
tients, samples were obtained before the second dialysis
session of the week.
Atherosclerosis assessment
Detailed and technical information on the methods to
evaluate subclinical atherosclerosis has been previously
published [18]. All studies were performed with a stan-
dardized protocol by three experienced itinerant teams
including a nurse and a radiology technician. These teams
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blood samples to be stored in the REDinRen (Spanish
Renal Research Network) centralized biobank for future
biomarker studies.
Participants underwent a carotid and femoral ultra-
sound to measure carotid intima-media thickness (cIMT)
and to evaluate the presence and characteristics of
atheromatous plaques, defined as a cIMT lumen pro-
trusion ≥1.5 mm, as recommended by the American
Society of Echocardiography [22]. cIMT was recorded as
the mean value between right and left common carotid
intima-media thicknesses. There is no current consensus
about the way to measure cIMT in patients with atheroma-
tous plaques in common carotid arteries. We propose to
use a right-truncated value of 1.5 mm in the presence of
plaques in the corresponding artery and then comput-
ing cIMT as the mean value between right and left
common-carotid arteries values (equivalent to the me-
dian of both values). Plaque presence in other carotid
territories was not evaluated for cIMT measurement.
Plaque presence was evaluated in left and right sides,
and in various territories (internal and common carotid
arteries and carotid bulbs, and common and superficial
femoral arteries).
Ankle-brachial index was measured using a protocolized
method, and the modified ABI was recorded. This is the
lowest value of the four available, and it was preferredTable 1 Baseline demographic and clinical characteristics of t
Controls CKD CKD stage 3 CKD st
n =559 n =2445 n =937 n =820
Male gender 298 (53.3) 1509 (61.7) 621 (66.3) 478 (58
Age (years) 54.6 ± 11.5 57.9 ± 12.8 60.9 ± 11.4 58.7 ±
Clinical history
Familial history of CVD 62 (11.1) 213 (8.7) 93 (9.9) 73 (8.9
Current smoker 109 (19.5) 474 (19.4) 177 (18.9) 158 (19
Former smoker 228 (40.8) 862 (35.3) 343 (36.6) 279 (34
Hypertension 197 (35.2) 2183 (89.3) 827 (88.3) 766 (93
Diabetes mellitus 61 (10.9) 628 (25.7) 258 (27.5) 246 (30
Dyslipidemia 196 (35.1) 1587 (64.9) 657 (70.1) 567 (69
CKD etiology N/A
Vascular 471 (19.3) 272 (29.1) 128 (15
Glomerular 381 (15.6) 110 (11.8) 150 (18
Diabetic 351 (14.4) 126 (13.5) 145 (17
Tubulointerstitial 287 (11.7) 94 (10.4) 100 (12
Cystic 239 (9.8) 58 (6.2) 85 (10.
Other 307 (12.5) 103 (10.6) 102 (12
Unknown 407 (16.7) 172 (18.4) 110 (13
Data expressed in number (%) or mean value ± standard deviation. Abbreviations: C
N/A not assessed.because it is the measure with a higher sensitivity for car-
diovascular risk assessment [23,24]. A pathologic ABI is
defined as a value <0.9, diagnostic of a limb ischemia,
or >1.4, diagnostic of arterial incompressibility and stiff-
ness, usually ascribed to vascular wall calcification.
An atherosclerosis score (AS) was originally designed
and described in the study rationale article [18], accord-
ing to these measures: AS0 (no atheromatosis), ABI >0.9
and cIMT <90th percentile of reference values; AS1 (mild),
ABI between 0.7-0.9 or cIMT ≥90th percentile of reference
values; AS2 (moderate), carotid plaque with stenosis <50-
70%; and AS3 (severe), ABI <0.7 or carotid plaque with
stenosis ≥70%.
Statistical analysis
Statistical analysis was performed using SPSS software,
version 17.0 (Chicago, Ill, USA) and R software [25].
Quantitative data are expressed as mean values ± standard
deviation, while qualitative variables are given in absolute
and relative frequencies. Normal distribution was assessed
by the Kolmogorov-Smirnoff test. Χ2 and Fisher exact’s
tests were used to compare categorical data, Student’s
t-test and Mann-Whitney’s U-test for continuous data,
ANOVA and Kruskal-Wallis’s H-test for comparison
of several groups and Pearson and Spearman’s coefficients
for numerical correlations. A significance level of 0.05 was
accepted.he patients
ages 4-5 CKD stage 5D p value p value
n =688 CKD vs controls Between CKD groups
.3) 409 (59.4) <0.001 <0.001
12.3 53.2 ± 13.8 <0.001 <0.001
) 47 (6.8) NS NS
.3) 175 (20.2) NS NS
.0) 204 (34.9) NS NS
.4) 590 (85.8) <0.001 <0.001
.0) 124 (18.0) <0.001 <0.001









KD chronic kidney disease, CVD cardiovascular disease, NS not significant,
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Main clinical and demographical data are summarized in
Table 1. Table 2 includes information related to anthro-
pometrical data and pharmacological treatments at en-
rolment, while Table 3 aggregates results of laboratory
values. Data are presented for total groups and for differ-
ent CKD stages. There are remarkable differences in age,
sex and prevalence and control of cardiovascular risk
factors between CKD patients and controls, but also be-
tween different CKD stages. These differences will pre-
sumably have an effect on subclinical atheromatosis.
Results of tests to detect subclinical atheromatosis are
showed in Table 4. There was no difference between
controls and CKD patients, but cIMT was lower in pa-
tients with more advanced CKD (Figure 1). Statistically
significant differences were shown when a model was
used in which plaques in common carotid arteries were
truncated to a cIMT value of 1.5 mm.
On the contrary, CKD patients presented a higher preva-
lence of atheromatous plaques, both globally and in carotid
and femoral arteries. No differences were found between
CKD stages. It is important to highlight a high rate of pa-
tients with femoral but not carotid plaques (Figure 2).Table 2 Baseline anthropometrical data and treatments at en
Controls CKD CKD stage 3
n =559 n =2445 n =937
Anthropometrical data
SBP (mmHg) 133.2 ± 17.7 142.9 ± 22.0 142.9 ± 20.2
DBP (mmHg) 80.0 ± 9.7 81.3 ± 11.9 81.6 ± 10.2
Pulse pressure (mmHg) 53.2 ± 13.0 61.6 ± 18.3 61.3 ± 16.9
BMI (Kg/m2) 28.1 ± 4.5 28.3 ± 5.2 29.2 ± 4.9
Abdominal obesity (%)* 47.8 49.6 58.9
Pharmacological treatments
Antihypertensive (%) 34.5 88.1 91.8
Hypolipidemic (%) 27.4 64.4 67.6
Antidiabetic (%) 9.5 21.9 23.5
Antiaggregation (%) 5.9 24.8 23.6
Anticoagulation (%) 0.5 3.1 3.2
Vitamin D (%) N/A 38.7 18.0
Of which active (%) N/A 32.1 12.0
Of wich native (%) N/A 10.2 7.0
Phosphate binders (%) N/A 35.7 5.7
Non-calcium based (%) N/A 22.2 1.0
Calcium based (%) N/A 21.1 4.9
ESA (%) N/A 35.6 5.7
Intravenous iron (%) N/A 18.7 1.7
Data expressed as percentage or mean value ± standard deviation. *Abdominal obe
aWaist circumference was not measured in peritoneal dialysis patients. Abbreviation
pressure, BMI body mass index, ESA erythropoiesis stimulating agents, N/A not asseSimilar results were found with the measure of ABI: higher
prevalence of pathologic values in CKD, with a progressive
rise of prevalence in more advanced CKD. Besides, as CKD
progresses, there are more patients with an ABI compatible
with vascular stiffness (ABI >1.4) and lower with an ABI
<0.9, compatible with distal ischemia (Figure 3).
Finally, AS was evaluated, with a higher rate of worse
scores in CKD patients, but no significant differences be-
tween stages.
Discussion
NEFRONA is the first large cohort study evaluating the
prevalence and evolution of subclinical atheromatosis in
CKD patients, aimed to define the role of non-invasive
early diagnostic tests.
Cardiovascular disease is the main cause of morbidity
and mortality in CKD patients, and it continues to be
so despite the better knowledge on vascular disease
pathogenesis and the improvement in CKD treatments
[1,21,26]. Appropriate evaluation of cardiovascular risk is
essential, and several non-invasive and easily performable
methods, like vascular ultrasound, are currently under
study.rolment
CKD stages 4-5 CKD stage 5D p value p value
n =820 n =688 CKD vs controls Between CKD
groups
146.7 ± 22.1 138.4 ± 23.4 <0.001 <0.001
82.2 ± 11.4 80.0 ± 14.2 0.010 0.005
64.5 ± 19.4 58.4 ± 18.3 <0.001 <0.001
28.8 ± 5.5 26.5 ± 4.9 NS <0.001
49.3 34.4a NS <0.001
95.6 74.3 <0.001 <0.001
70.7 52.5 <0.001 <0.001
25.2 15.8 <0.001 <0.001
23.8 27.6 <0.001 NS
3.0 3.2 <0.001 NS
50.4 53.1 N/A <0.001
42.8 46.9 N/A <0.001
13.6 10.6 N/A <0.001
31.1 82.0 N/A <0.001
14.7 60.1 N/A <0.001
20.4 43.8 N/A <0.001
32.2 80.4 N/A <0.001
8.2 54.5 N/A <0.001
sity defined as waist circumference >88 cm in women and >102 cm in men.
s: CKD chronic kidney disease, SBP systolic blood pressure, DBP diastolic blood
ssed, NS not significant.
Table 3 Baseline laboratory values
Controls CKD CKD stage 3 CKD stages 4-5 CKD stage 5D p value p value
n =559 n =2445 n =937 n =820 n =688 CKD vs controls Between CKD
groups
Creatinine (mg/dL) 0.8 ± 0.2 4.1 ± 3.3 1.6 ± 0.4 3.3 ± 1.3 8.4 ± 2.9 <0.001 <0.001
MDRD (mL/min/1.73 m2) 91.8 ± 16.8 N/A 43.5 ± 8.7 20.6 ± 7.5 N/A N/A N/A
Urea (mg/dL) 37.4 ± 9.1 101.6 ± 48.1 65.3 ± 24.3 121.9 ± 47.5 126.1 ± 42.9 <0.001 <0.001
Total cholesterol (mg/dL) 203.4 ± 35.6 178.3 ± 39.7 187.4 ± 36.5 179.1 ± 37.9 164.9 ± 42.4 <0.001 <0.001
LDL-cholesterol (mg/dL) 127.3 ± 32.8 101.8 ± 33.7 109.6 ± 31.6 101.9 ± 32.7 91.2 ± 34.8 <0.001 <0.001
HDL-cholesterol (mg/dL) 53.9 ± 15.4 49.3 ± 15.4 50.9 ± 15.4 49.2 ± 15.1 47.3 ± 15.6 <0.001 <0.001
No-HDL-cholesterol (mg/dL) 150.4 ± 36.1 129.3 ± 37.4 136.8 ± 34.5 130.6 ± 36.3 117.8 ± 39.7 <0.001 <0.001
Triglycerides (mg/dL) 115.5 ± 67.5 145.0 ± 82.3 144.7 ± 83.0 149.8 ± 85.7 139.7 ± 76.1 <0.001 NS
Glucose (mg/dL) 101.4 ± 23.6 107.6 ± 39.4 110.8 ± 37.4 108.4 ± 41.4 102.3 ± 39.2 NS NS
Hemoglobin (g/dL) 14.5 ± 1.4 12.8 ± 1.7 13.8 ± 1.7 12.4 ± 1.4 11.9 ± 1.4 <0.001 <0.001
Transferrin (mg/dL) 283.4 ± 47.1 220.1 ± 48.8 245.9 ± 48.0 220.7 ± 42.2 193.3 ± 41.7 <0.001 <0.001
TSAT (%) 24.9 ± 12.4 27.8 ± 12.5 25.8 ± 10.5 27.3 ± 10.6 30.4 ± 15.5 0.003 <0.001
Ferritin (ng/mL) 113.8 ± 116.7 244.2 ± 308.8 170.7 ± 215.1 190.2 ± 167.7 365.5 ± 440.8 <0.001 <0.001
Uric acid (mg/dL) 5.1 ± 1.4 6.7 ± 1.6 6.8 ± 1.6 7.0 ± 1.6 6.1 ± 1.3 <0.001 <0.001
hsCRP (mg/L) 3.4 ± 7.9 4.7 ± 9.3 3.9 ± 6.1 4.8 ± 9.9 5.6 ± 11.7 <0.001 0.020
Albumin (g/dL) 4.4 ± 0.3 4.1 ± 0.4 4.2 ± 0.4 4.1 ± 0.5 3.9 ± 0.5 <0.001 <0.001
Corrected calcium (mg/dL) 9.4 ± 0.4a 9.2 ± 0.6 9.5 ± 0.5 9.3 ± 0.6 9.1 ± 0.7 <0.001 <0.001
Phosphorus (mg/dL) 3.5 ± 0.5a 4.1 ± 1.1 3.4 ± 0.6 4.1 ± 0.8 4.9 ± 1.3 <0.001 <0.001
Intact PTH (pg/mL) N/A 181.7 ± 193.5 85.6 ± 69.0 173.5 ± 123.8 297.1 ± 273.2 N/A <0.001
25-hydroxi-vitamin D (ng/L) 20.1 ± 7.9 16.1 ± 7.5 16.7 ± 7.8 16.2 ± 6.8 15.1 ± 7.4 <0.001 <0.001
1,25-hydroxi-vitamin D (pg/mL) 33.6 ± 13.9 16.8 ± 10.9 21.5 ± 11.2 17.4 ± 10.0 8.3 ± 5.1 <0.001 <0.001
Data expressed as mean value ± standard deviation. aData available in 36% of subjects. Abbreviations: CKD chronic kidney disease, MDRD glomerular filtration rate
estimated with the 4-variable MDRD equation, TSAT transferring saturation, PTH parathyroid hormone, hsCRP high-sensitivity C reactive protein, N/A not assessed,
NS not significant.
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a higher age and proportion of male subjects, and higher
rates of hypertension, diabetes and dyslipidemia than the
controls. However, this worse cardiovascular profile is
more pronounced in earlier stages of CKD. The percent-
age of diabetic and vascular etiologies of CKD is propor-
tionally lower in more advanced stages. Blood pressure
values and BMI equally show this trend. These facts
could be explained by an incidence-prevalence bias (or
Neyman bias), since as renal dysfunction progresses,
patients with worse cardiovascular health have a lower
possibility of staying free of cardiovascular events, and
hence, of being recruited for this study. There is prob-
ably a selection bias too, given that patients in CKD
stage 5d were significantly younger, and age has been
shown the most important risk factor for atheromatosis
development. It is also rather remarkable the high rate
of well-known cardiovascular risk factors in stage 3 CKD
patients. Altogether, it seems increasingly important and
evidence-based that primary prevention strategies must
be started earlier in the course of the disease.All evaluated pharmacological treatments are much
more frequently prescribed in CKD patients than in con-
trols, as it was expected. Antihypertensive, antidiabetic
and hypolipidemic drugs are more common in CKD
stages 4-5 than in stage 3, but in dialysis these treatments
are much less frequent. This tendency is explained by the
baseline differences, but also by the well-known reverse
epidemiology effect in cardiovascular risk factors: dialysis
patients usually have lower LDL-cholesterol levels, so they
are prescribed less statins.
On the other side, treatments for control of anemia
and mineral-bone disorders grow exponentially in more
advanced CKD stages. Two interesting pieces of infor-
mation can be highlighted: first, a very low percentage of
patients treated with native vitamin D regardless of the
stage, despite the usually low plasma levels and the
growing evidence of the benefits of vitamin D supple-
mentation [27-30]; second, the high rate of patients in
more advanced stages of CKD receiving calcium-based
phosphate binders, despite their extremely high risk of
vascular calcification.
Table 4 Subclinical atheromatosis detection in CKD and non-CKD patients
Controls CKD CKD stage 3 CKD stages 4-5 CKD stage 5D p value p value





All patientsa 0.705 (0.605-0.815) 0.725 (0.615-0.870) 0.765 (0.645-0.891) 0.705 (0.600-0.855) 0.695 (0.595-0.850) <0.001 <0.001
Plaque-free common carotidb 0.710 ± 0.150 0.710 ± 0.160 0.749 ± 0.164 0.699 ± 0.157 0.689 ± 0.154 NS <0.001
Atheroma plaque
presence (%)
Any territory 52.4 70.0 70.5 69.6 70.0 <0.001 NS
Only carotid artery 18.1 18.8 19.3 17.6 19.4 <0.001 NS
Only femoral artery 10.0 12.6 12.9 13.3 11.2 <0.001 NS
Carotid and femoral arteries 24.3 38.7 38.3 38.6 39.3 <0.001 NS
ABI
Mean ABI 1.03 ± 0.10 1.06 ± 0.27 1.02 ± 0.19 1.05 ± 0.21 1.14 ± 0.38 NS <0.001
Pathologic ABI (%) 12.3 28.0 25.3 27.1 32.9 <0.001 0.003
ABI >1.4 (%) 1.4 11.0 5.6 10.2 19.5 <0.001 <0.001
ABI <0.9 (%) 10.9 17.0 19.8 16.9 13.4 <0.001 0.003
Atheromatosis score (%) <0.001 NS
AS 0 38.1 30.3 28.4 33.4 29.3
AS 1 20.0 11.5 13.1 9.9 11.0
AS 2 41.7 53.5 54.1 51.5 55.2
AS 3 0.0 4.4 4.2 5.0 4.1
Data expressed as percentage or mean value ± standard deviation. aValues for all the patients, truncating IMT values of patients with plaques at 1.5 mm. Data
expressed as median (interquartile interval). bValues for patients with no plaque in any common carotid artery. Abbreviations: CKD chronic kidney disease, cIMT
common carotid intima-media thickness, ABI ankle-brachial index, AS atheromatosis score, NS not significant.
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values show that patients are globally well controlled,
and we confirm the reverse epidemiology phenomenon
in lipids (the frequently described tendency to spontan-
eously normalize their lipid profile in end-stage renal
disease, that has been associated to more inflamma-
tion and malnutrition). It is important to highlight the
low values of inflammation markers in all CKD stages.
Anemia and mineral-bone disorder parameter analysis
appear to show a mainly good adherence to current
guidelines, at least in this subpopulation free of cardiovas-
cular history.
cIMT is a good cardiovascular risk marker in subjects
with normal renal function [31,32]. A few studies have also
proved that cIMT can predict ischemic events in CKD pa-
tients, but most of them were conducted in dialysis pa-
tients with small sample sizes [33-37]. In the NEFRONA
study, we did not find any difference in cIMT between
CKD patients and controls, unless plaque presence was
corrected to a higher cIMT value. However, we did find
that cIMT was higher in CKD stage 3, and progressively
lower with more advanced stages. Again, there seems to
be a survival bias involved, given the cross-sectional na-
ture of this data, and an incidence-prevalence bias, since
only patients free of prior cardiovascular events wereincluded. It is likely that patients with more advanced
CKD have a lower cIMT because those who would have
had a higher cIMT probably already had a cardiovascular
event. It is a well-known factor that CKD patients have a
higher chance of suffering a fatal or non-fatal vascular
event than eventually requiring dialysis, so those patients
arriving to more advance CKD stages are usually consid-
ered “cardiovascular survivors” [21]. This fact should be
proved in the prospective analysis of the NEFRONA study.
More specific data about cIMT, such as different site mea-
sures or differences between left and right cIMT, is under
current analysis.
Atheromatous plaque presence directly affects cardio-
vascular prognosis in general population [38], and it
seems clearly involved in CKD morbimortality [39].
There is evidence showing the predictive effect of the
presence and extent of vascular plaques on dialysis pa-
tients [40,41]. Besides, the place where calcium is depos-
ited is also important: it seems that intimal rather than
medial calcification has a worse prognosis [42-44]. In
our study, plaque prevalence is significantly higher in
CKD patients than in subjects with normal renal func-
tion, but there is no difference between CKD stages. We
explain this fact by the same biases as for cIMT; age
seems to be the main determinant for the atheromatous
Figure 1 Mean carotid intima-media thickness in controls and chronic kidney disease patients. Distribution of carotid intima-media
thickness (cIMT) in controls and in different chronic kidney disease (CKD) stages. a) Patients without plaques in common carotid arteries.
b) All patients (plaques truncated at 1.5 mm). *p <0.001.
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stage 5 CKD free of cardiovascular events.
One interesting finding is the high rate of femoral pla-
ques, even in patients with no carotid atheromatosis
(between 10 and 12%). Some studies have started to ex-
plore the evaluation of ultrasound diagnosis of femoralFigure 2 Plaque presence in carotid and femoral ultrasound.
Prevalence and distribution of atheromatous plaques in carotid
and/or femoral arteries in both controls and chronic kidney disease
(CKD) patients.plaques in general population and in other pathologies
[45,46]. In CKD, evaluation of this site has been studied
by simple radiology, and it has been associated to periph-
eral artery disease and cardiovascular prognosis [47]. In
order to perform an adequate vascular risk assessment,
femoral ultrasound should complement carotid ultra-
sound. More extensive data on the specific characteristicsFigure 3 Pathologic ankle-brachial index in controls and chronic
kidney disease patients. Prevalence of pathologic ankle-brachial index
(ABI) and variation of ABI <0.9 and ABI >1.4 through chronic kidney
disease (CKD) stages. *p <0.001.
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groups is beyond the aim of this article, and it has par-
tially been published [48].
Peripheral artery disease, defined as a pathologic
ankle-brachial index has also shown to have a predictive
value over new-onset cardiovascular events in non-CKD
[49,50] and CKD subjects [51-53], but again, most data
come from dialysis cohorts. In the NEFRONA study,
CKD was associated with a pathologic ABI. In more
advanced stages of CKD, pathologic ABI was more fre-
quently in the higher rank (>1.4, related to severe vascu-
lar calcification) than in the ischemic range (<0.9).
Altogether, CKD patients present a higher atheroma-
tous score than non-CKD subjects, but no difference
could be found between CKD stages, probably due to
the cross-sectional nature of this initial analysis and the
uneven distribution of cardiovascular risk factors. Fur-
ther and more complete information will be revealed
when follow-up data are published.
This study has some limitations, being the first one
the cross-sectional nature of these initial results. There
is an intentional bias, because only patients with no history
of cardiovascular events were included. This bias was ne-
cessary, but its consequences have to be considered when
interpreting the results. Finally, control subjects are not
perfectly matched, and also present a selection bias: they
were selected from patients seeking medical attention in
Primary Care centers, so they might not be a fully repre-
sentative sample of the general population.
Conclusions
NEFRONA is the first study presenting the real preva-
lence of subclinical atheromatosis in a large cohort of
CKD patients, compared to subjects with normal renal
function. As an added value, all diagnostic tests were
performed by the same exploration teams, avoiding dif-
ferences between observers.
The cardiovascular risk profiles and treatment policies
through different CKD stages is also presented. Our re-
sults indirectly suggest that patients with more advanced
renal dysfunction are those who have avoided cardiovas-
cular events.
Subclinical atheromatosis is very prevalent in chronic
kidney disease patients. Femoral atheromatous plaques are
very frequent, even in patients without carotid plaques;
hence, femoral ultrasound should also be performed for a
correct evaluation of cardiovascular risk. Further data on
the evolution and prognosis of subclinical atheromatosis
will contribute to the understanding of atheromatous dis-
ease in kidney disease when the prospective analysis of the
NEFRONA study is published. This initial analysis should
generate new hypothesis and stimulate the study of the
effect of earlier primary prevention strategies on cardiovas-
cular morbidity in CKD patients.Competing interests
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